The treatment of chronic lymphocytic leukemia (CLL) has undergone a paradigm shift as the mainstay has transitioned from CIT to targeted novel agents, including Bruton Tyrosine Kinase inhibitors (BTKi) and the B-cell lymphoma 2 (BCL2) inhibitor venetoclax. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.